$NNOXJul 7, 2026, 8:10 AM ETAI processed
NNOX: Nanox to present Nanox.AI cardiac study data at SCCT 2026 showing high agreement with experts
AI Summary
Nanox said new data featuring its FDA-cleared Nanox.AI cardiac solution (HealthCCSng) will be presented at SCCT 2026, including initial findings from the multi-site AI INFORM randomized trial and a multi-site analysis comparing AI-detected coronary artery calcium to expert visual assessment. The abstracts report high agreement with expert readings and suggest AI-detected incidental coronary calcium could identify opportunities for preventive lipid‐lowering therapy; posters are scheduled for July 11 and the company is sponsoring a related SCCT session.
Positives
- Data includes initial results from a multi-site randomized trial (AI INFORM) and a multi-site agreement analysis
- Nanox.AI cardiac solution (HealthCCSng) is described as FDA‑cleared
- Abstracts report high agreement between AI coronary calcium detection and expert visual assessment and potential to flag patients for preventive therapy
Negatives
- Results presented as conference abstracts/posters (preliminary, not peer‑reviewed outcome data)
- Release notes some referenced technology remains under development and may not be commercially available or cleared for clinical use